Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a conference call on Monday, May 9, 2022 at 10:30 a.m. ET to review top-line clinical data from its “ASTRAEUS” Phase 2 Study of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema.
